New initiatives are being explored in France to expand the role of pharmacies in addressing public health issues such as arterial hypertension, smoking cessation, and type 2 diabetes management. These proposals are part of ongoing discussions under the third annex of the national pharmaceutical convention, which outlines agreements between the government and the pharmaceutical industry. For arterial hypertension, or HTA, pharmacies could help identify patients who may not be aware they have high blood pressure. Pharmacists might measure blood pressure, assess risk factors, and refer individuals to doctors if needed. This would help patients start or continue their care pathway and ensure regular follow-ups during future visits to the pharmacy. The goal is to detect HTA early and support patients in managing their condition. In three regions—Hauts-de-France, Nouvelle-Aquitaine, and Provence-Alpes-Côte d'Azur—a two-year experiment is underway to help people quit smoking. In each region, one or two departments will participate, and all pharmacies within them will be able to take part. The program includes four interviews with patients over six months, starting with an initial meeting and three follow-ups. Researchers will evaluate how well pharmacists follow the protocol, how many patients are recruited, and how many stay in the program. Smoking cessation rates will be measured at six months and one year. The use of nicotine substitutes, such as patches or gum, will also be recorded, and how pharmacists are compensated for their time is still being discussed, possibly using existing payment models for pharmaceutical support. For type 2 diabetes, pharmacies may begin offering support in the coming months. An initial interview will help identify a patient's needs and set priorities. Seven key topics have been selected, including understanding the disease, treatment options, adherence to medication, monitoring blood sugar levels, complications, dietary guidelines, and physical activity. Pharmacists will be able to address three of these topics each year. The compensation for this service is still being negotiated, and it may be based on current rates for pharmaceutical support. Compensation for these new services is still under discussion, with some reports suggesting that pharmacists could be paid between 10 and 25 euros for detecting arterial hypertension. The exact amounts for other services remain to be determined, but the goal is to provide pharmacists with fair payment while expanding access to essential health services for the public.